Dr. Narayan on efficacy, tolerability of nadofaragene firadenovec in BCG-unresponsive NMIBC

January 11, 2021
Urology Times staff

Vikram M. Narayan, MD, discusses the high complete response rate and manageable safety profile with nadofaragene firadenovec in BCG-unresponsive non-muscle invasive bladder cancer.

Vikram M. Narayan, MD, highlights efficacy and safety data with the novel intravesical gene-mediated therapy nadofaragene firadenovec in patients with high-grade, BCG-unresponsive non-muscle invasive bladder cancer.

In a phase 3 trial nadofaragene firadenovec achieved a complete response (CR) rate of 53.4% at 3 months in a subgroup of patients with carcinoma in situ with or without concomitant high-grade Ta or T1 disease. The 12-month CR rate was 24.3% and the median duration of CR was 9.69 months in these patients.